Data gathered: September 21
Alternative Data for Illumina
About Illumina
Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function.
| Price | $131.20 |
| Target Price | Sign up |
| Volume | 2,570,000 |
| Market Cap | $21.4B |
| Year Range | $98.3 - $143.19 |
| Dividend Yield | 0% |
| PE Ratio | 91.22 |
| Industry | Biotechnology |
In the news
 |
Ameritas Investment Partners Inc. Raises Stock Position in Illumina, Inc. (NASDAQ:ILMN)September 21 - ETF Daily News |
|
14,559 Shares in Illumina, Inc. (NASDAQ:ILMN) Purchased by Symmetry Investments LPSeptember 21 - ETF Daily News |
|
Meiji Yasuda Asset Management Co Ltd. Raises Stock Position in Illumina, Inc. (NASDAQ:ILMN)September 21 - ETF Daily News |
|
Amalgamated Bank Boosts Stake in Illumina, Inc. (NASDAQ:ILMN)September 20 - ETF Daily News |
|
Tredje AP fonden Has $2.58 Million Holdings in Illumina, Inc. (NASDAQ:ILMN)September 20 - ETF Daily News |
|
Moors & Cabot Inc. Trims Stake in Illumina, Inc. (NASDAQ:ILMN)September 20 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '24 | 1.11B | 391M | 721M | -1.99B | -1.59B | 0.360 |
| Q1 '24 | 1.08B | 409M | 667M | -126M | -42M | 0.090 |
| Q4 '23 | 1.12B | 448M | 674M | -176M | -100M | 0.140 |
| Q3 '23 | 1.12B | 435M | 684M | -754M | -714M | 0.330 |
| Q2 '23 | 1.18B | 444M | 732M | -234M | -21M | 0.320 |
Insider Transactions View All
| Thaysen Jacob filed to buy 14,861 shares at $137.2. February 26 '24 |
| Thaysen Jacob filed to buy 14,169 shares at $135.7. February 26 '24 |
| Thaysen Jacob filed to buy 12,616 shares at $134.9. February 26 '24 |
| Hoyt Aimee L filed to sell 8,314 shares at $112.8. November 9 '23 |
| TOUSI SUSAN H filed to sell 45,524 shares at $167. August 24 '23 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Rohit Khanna Democrat |
Jun 5, 24 | Buy | $1K - $15K |
| Rohit Khanna Democrat |
Jun 5, 24 | Sell | $1K - $15K |
| Thomas Kean Jr Republican |
May 30, 24 | Buy | $1K - $15K |
Read more about Illumina (ILMN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Illumina?
The Market Cap of Illumina is $21.4B.
What is Illumina's PE Ratio?
As of today, Illumina's PE (Price to Earnings) ratio is 91.22.
What is the current stock price of Illumina?
Currently, the price of one share of Illumina stock is $131.20.
How can I analyze the ILMN stock price chart for investment decisions?
The ILMN stock price chart above provides a comprehensive visual representation of Illumina's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Illumina shares. Our platform offers an up-to-date ILMN stock price chart, along with technical data analysis and alternative data insights.
Does ILMN offer dividends to its shareholders?
As of our latest update, Illumina (ILMN) does not offer dividends to its shareholders. Investors interested in Illumina should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Illumina?
Some of the similar stocks of Illumina are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.